GT Biopharma (GTBP) Total Liabilities (2010 - 2026)

GT Biopharma (GTBP) has reported Total Liabilities for 17 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Liabilities fell 33.59% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 33.59% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 60.71% from the prior year.
• Total Liabilities was $2.4 million for Q1 2026 at GT Biopharma, up from $2.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $31.0 million in Q2 2025 and troughed at -$5.5 million in Q2 2024.
• A 5-year average of $6.2 million and a median of $5.1 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 186.32% in 2024 and soared 663.6% in 2025, its largest moves.
• Over 5 years, Total Liabilities stood at $5.0 million in 2022, then soared by 32.61% to $6.6 million in 2023, then retreated by 11.02% to $5.9 million in 2024, then sank by 60.71% to $2.3 million in 2025, then increased by 4.18% to $2.4 million in 2026.
• The last three Total Liabilities figures came in at $2.4 million (Q1 2026), $2.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.